Skip to main content

8 Result(s)

within Carla Strina Remove this filter

and

  1. Article

    Open Access

    Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

    Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris… in npj Breast Cancer (2024)

    Download PDF (378 KB) View Article

  2. Article

    Open Access

    Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

    Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris… in npj Breast Cancer (2023)

    Download PDF (380 KB) View Article

  3. Article

    Open Access

    Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

    The combination of atezolizumab and nab-paclitaxel is recommended in the EU as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer (mTNBC), based on the results of phase III IMpass...

    Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris… in npj Breast Cancer (2023)

    Download PDF (913 KB) View Article

  4. Article

    Open Access

    Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib

    Mathematical models based on partial differential equations (PDEs) can be exploited to handle clinical data with space/time dimensions, e.g. tumor growth challenged by neoadjuvant therapy. A model based on sim...

    Francesco Schettini, Maria Valeria De Bonis, Carla Strina… in Scientific Reports (2023)

    Download PDF (1376 KB) View Article

  5. Article

    Open Access

    Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study

    mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other sol...

    Francesco Schettini, Navid Sobhani, Anna Ianza… in Breast Cancer Research and Treatment (2020)

    Download PDF (4695 KB) View Article

  6. No Access

    Article

    Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR

    Neoadjuvant hormonal therapy is generally considered a valid option for hormone receptor positive breast cancer (BC) patients who are unfit for chemotherapy or surgery.

    Daniele Generali, Silvia Paola Corona… in Journal of Cancer Research and Clinical On… (2018)

  7. No Access

    Article

    Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the “biological window therapy”

    The study investigated the anti-tumour effect of zoledronic acid (ZA) administered alone in a biological window therapy in naïve bone-only metastatic and locally advanced breast cancer (LABC) patients. 33 pat...

    Chiara Foroni, Manuela Milan, Carla Strina… in Breast Cancer Research and Treatment (2014)

  8. No Access

    Article

    Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

    Introduction: Single agent gemcitabine (GEM) is the standard treatment of pancreatic adenocarcinoma. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor. Recent studies in human p...

    Vittorio Ferrari, Francesca Valcamonico… in Cancer Chemotherapy and Pharmacology (2006)